Thematic area:
Advanced Wearables
Product:
A novel, nonthermal localised compression therapy (LCT) device designed to prevent chemotherapy induced mucositis by reducing blood flow to the oral mucosa during drug infusion. The device is lightweight, wearable, and built to apply safe, consistent buccal pressure to prevent painful ulceration.
Market:
Serves the global oral mucositis prevention and oncology supportive care market, valued at $1.6B in 2023 and growing. Primary customers include oncology centres, chemotherapy suites, cancer patients, and MedTech companies already delivering chemotherapy side effect mitigation products.
Fit:
Current mucositis treatments focus on symptom relief rather than prevention and have poor patient adherence. MucoCare directly addresses this gap with an evidence-based, affordable, scalable intervention with strong prior IP and clinical validation.
